Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Oaktree Acquisition Corp. III Life Sciences Warrant (OACCW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: OACCW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.09% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.36 - 1.24 | Updated Date 06/14/2025 |
52 Weeks Range 0.36 - 1.24 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Warrant
Company Overview
History and Background
Oaktree Acquisition Corp. III was a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The lifespan of the warrant is dependent on the completion and specifics of the SPAC's initial business combination.
Core Business Areas
- SPAC Formation: Creation of a special purpose acquisition company (SPAC) to identify and acquire a private business in the life sciences sector.
- Acquisition Process: Due diligence, negotiation, and completion of a merger or acquisition with a target company.
Leadership and Structure
Oaktree Acquisition Corp. III likely had a management team experienced in investment and the life sciences sector, headed by a CEO or equivalent, and structured as a publicly traded company.
Top Products and Market Share
Key Offerings
- Warrant: A warrant represents the right to purchase shares of the SPAC's common stock at a specified price and within a specific timeframe. Market share is not applicable to warrants. The warrant's value is derived from the underlying SPAC stock and the potential value of the merged entity. Competitors are other warrants of similar SPACs.
Market Dynamics
Industry Overview
The SPAC market is cyclical, influenced by investor sentiment and regulatory changes. The life sciences sector is attractive due to its growth potential, but involves high risk and regulatory hurdles.
Positioning
Oaktree Acquisition Corp. III aimed to leverage Oaktree's investment expertise to identify and acquire a promising life sciences company. Success depended on finding a suitable target and completing the acquisition.
Total Addressable Market (TAM)
The TAM is the entire life sciences industry. Oaktree's positioning was to capture a segment of this TAM by acquiring a high-growth company within the space.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Access to Oaktree's network and capital
- Focus on the high-growth life sciences sector
Weaknesses
- Dependence on finding a suitable acquisition target
- SPAC structure inherently dilutive to shareholders
- Market risk associated with the life sciences sector
Opportunities
- Potential to acquire a disruptive life sciences company
- Benefit from favorable regulatory changes
- Capitalize on increased investor interest in healthcare
Threats
- Inability to find a suitable acquisition target
- Increased competition from other SPACs
- Regulatory hurdles in the life sciences sector
- Economic downturn impacting the healthcare industry
Competitors and Market Share
Key Competitors
Competitive Landscape
The SPAC market is highly competitive, with numerous SPACs vying for acquisition targets. Oaktree's advantage was its experience and access to capital.
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Dependent on the acquired company's growth prospects.
Recent Initiatives: Identifying and pursuing potential acquisition targets.
Summary
Oaktree Acquisition Corp. III Life Sciences Warrant represented an investment in the potential success of a SPAC targeting the life sciences sector. The warrant's value was contingent on the SPAC finding a suitable acquisition target and successfully completing the merger. Success hinged on the acquired company's subsequent performance, making it a high-risk, high-reward investment. Regulatory hurdles and market competition were significant factors influencing its ultimate outcome.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. The value of SPAC warrants is highly volatile and subject to market risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Warrant
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-12-16 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.